血管紧张素Ⅱ受体拮抗剂——缬沙坦

Valsartan - A New Approaching to the Antihypertensive Therapy

血管紧张素Ⅱ受体拮抗剂的问世和发展,为抑制肾素-血管紧张素-醛固酮系统寻找到了一类新型药物。它是继β受体阻滞剂、钙拮抗剂、血管紧张素转换酶抑制剂后的又一新的突破,并拓展了抗高血压药的作用途径。其代表药物缬沙坦疗效显著,对AT_1受体具高度选择性,药效可持续24小时,不良反应极小,具有广阔的应用前景。

Angiotensin Ⅱ , an active medium in renin - angiotensin - aldosterone system and believed to play an important role in developing hypertension and consequently the target organ damaging, has been extensively studied in recent years. As a result, an angiotensin Ⅱ receptor antagonist, Valsartan, was developed and then launched firstly in Germany in 1996, and is now waiting for registration in China. Valsartan is a new type of antihypertensives after the β - blockers, calcium channel antagonists and ACEI, and is the 2nd A - Ⅱ I - A non - peptide, non pro - drug after . losartan with higher selectivity to AT1 receptor, better oral absorption, longer duration of action (up to 24 hrs. ), and less adverse reactions.